Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
12.81
-0.44 (-3.32%)
At close: Apr 28, 2026, 4:00 PM EDT
13.06
+0.25 (1.95%)
After-hours: Apr 28, 2026, 5:48 PM EDT
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Cullinan Therapeutics stock have an average target of 30.13, with a low estimate of 22 and a high estimate of 38. The average target predicts an increase of 135.21% from the current stock price of 12.81.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cullinan Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 8 | 7 | 6 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 10 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $27 → $30 | Strong Buy | Maintains | $27 → $30 | +134.19% | Apr 28, 2026 |
| Wedbush | Wedbush | Buy Maintains $34 → $36 | Buy | Maintains | $34 → $36 | +181.03% | Mar 11, 2026 |
| Citigroup | Citigroup | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +157.61% | Feb 17, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +134.19% | Feb 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $26 → $27 | Strong Buy | Maintains | $26 → $27 | +110.77% | Jan 8, 2026 |
Financial Forecast
Revenue This Year
25.61M
Revenue Next Year
26.94M
from 25.61M
Increased by 5.20%
EPS This Year
-3.01
from -3.72
EPS Next Year
-2.91
from -3.01
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 109.2M | 105.0M | ||||||
| Avg | 25.6M | 26.9M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 309.9% | ||||||
| Avg | - | 5.2% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.19 | -1.08 | ||||||
| Avg | -3.01 | -2.91 | ||||||
| Low | -3.62 | -3.99 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.